

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 381-86	SERIAL NO. Unassigned	1c841 U.S. PTO 09/635974 08/09/00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	APPLICANT Thomas Teufel		
	FILING DATE Herewith	GROUP Unassigned	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
⑧	4,816,397	03/28/89	Boss, et al.	_____	_____	
↓	5,196,446	03/23/93	Levitzki, et al.	_____	_____	
	5,550,114	08/27/96	Strayer	_____	_____	
	5,646,153	07/08/97	Spada, et al.	_____	_____	
	5,656,655	08/12/97	Spada, et al.	_____	_____	
	5,679,683	10/21/97	Bridges, et al.	_____	_____	
	5,789,427	08/04/98	Chen, et al.	_____	_____	
	5,851,999	12/22/98	Ullrich, et al.	_____	_____	
	5,861,499	01/19/99	Rockwell, et al.	_____	_____	
	5,869,465	02/09/99	Morgan, Jr. et al.	_____	_____	
	5,914,269	06/22/99	Bennett, et al.	_____	_____	
	5,925,566	07/20/99	Davis, et al.	_____	_____	
	5,955,311	09/21/99	Rockwell, et al.	_____	_____	
↙	6,004,967	12/21/99	McMahon, et al.	_____	_____	

EXAMINER



DATE CONSIDERED

5/20/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 381-86	SERIAL NO. Unassigned
	APPLICANT Thomas Teufel	
	FILING DATE Herewith	GROUP Unassigned

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
<i>PT</i>	<input checked="" type="checkbox"/>	PCT/AU99/00 420	05/31/99	Europe				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>PT</i>	<input checked="" type="checkbox"/>	Green, Larry L, "Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies," <i>Journal of Immunological Methods</i> , # 231:11-23 (1999).
	<input checked="" type="checkbox"/>	Jost, et al., "A Central Role of Bcl-X _L in the Regulation of Keratinocyte Survival by Autocrine EGFR Ligands," <i>The Journal of Investigative Dermatology</i> , # 112:443-449 (1999).
	<input checked="" type="checkbox"/>	Kao, et al., "Comparison of the Effect of 8-Methoxypsoralen (8-MOP) plus UVA (PUVA) on Human Melanocytes in Vitiligo Vulgaris and <i>In Vitro</i> ," <i>The Journal of Investigative Dermatology</i> , # 98(5):734-740 (1992).
	<input checked="" type="checkbox"/>	Rikimaru, et al., "Correlation between hyperproliferation and suprabasal integrin expression in human epidermis reconstituted in culture," <i>Experimental Dermatology</i> , #6:214-221 (1997)
	<input checked="" type="checkbox"/>	Gottlieb, et al., "Detection of Transforming Growth Factor α in Normal, Malignant, and Hyperproliferative Human Keratinocytes," <i>Brief Definitive Report</i> , # 167:670-675 (1998).
	<input checked="" type="checkbox"/>	Fransson et al., "Epidermal growth in the skin equivalent," <i>Archives of Dermatological Research</i> , # 284:343-348 (1992)
	<input checked="" type="checkbox"/>	Castelijns, et al., "The epidermal phenotype during initiation of the psoriatic lesion in the symptomless margin of relapsing psoriasis," <i>Journal of the American Academy of Dermatology</i> , # 40:901-9 (1999).
EXAMINER		DATE CONSIDERED 5/20/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

EXAMINER DATE CONSIDERED 5/20/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 381-86	SERIAL NO. Unassigned
	APPLICANT Thomas Teufel	
	FILING DATE Herewith	GROUP Unassigned

A			Abgenix, Inc. Press Release, "Abgenix Initites Phase III Clinical Trial with ABX-IL8 in Psoriasis," April 3, 2000,

EXAMINER

DATE CONSIDERED

5/20/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT
BY APPLICANT PTO-1449**

**ATTY. DOCKET NO.
11245/48601**

**SERIAL NO.
09/635,974**

**APPLICANT
T. TEUFEL**

**FILING DATE
August 9, 2000**

**GROUP
1642**

**RECEIVED
APR 25 2002
TECH CENTER 1600/21**

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
	4,943,533	July 24, 1990	Mendelsohn et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
DB	WO 99/60023	November 25, 1999	PCT				

OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
DB	✓	Huang et al., "Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck", Cancer Research, April 15, 1999, vol. 59, pp. 1935-1940
DB	✓	Laskin et al., "Psoralens potentiate ultraviolet light-induced inhibition of epidermal growth factor binding", PNAS, November 1986, vol. 83, pp. 8211-8215

EXAMINER *DB* *DB* **DATE CONSIDERED** 5/20/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

465641

**COPY OF PAPERS
ORIGINALLY FILED**